Prostate Cancer News and Research

Latest Prostate Cancer News and Research

Extra dose of proton radiation therapy reduces prostate cancer recurrences

Men who receive a "boost" of proton therapy after receiving a standard course of X-ray radiation therapy have fewer recurrences of their prostate cancer compared to men who did not receive the extra dose of proton radiation, according to a first-of-its-kind study presented November 2, 2009, at the American Society for Radiation Oncology's 51st Annual Meeting in Chicago.

3 Nov 2009

superDimension launches the iLogic electromagnetic navigation bronchoscopy tool

superDimension, Inc.®, a private company that develops minimally invasive interventional pulmonology devices, announced today the launch of the iLogic System for early lung cancer detection and diagnosis. The device is the second generation version of inReach(TM), superDimension's electromagnetic navigation bronchoscopy (ENB) minimally invasive tool.

2 Nov 2009

Dendreon submits an amended BLA for PROVENGE active cellular immunotherapy

Dendreon Corporation today announced that it has completed the submission of the amended Biologics License Application (BLA) for PROVENGE® (sipuleucel-T), the Company's lead investigational product, to the U.S. Food and Drug Administration (FDA). Dendreon is seeking licensure for PROVENGE for men with metastatic castrate-resistant prostate cancer (CRPC).

2 Nov 2009

FDA issues a Complete Response Letter for GTx' toremifene NDA

GTx, Inc. today announced that it has received a Complete Response Letter issued by the United States Food and Drug Administration (FDA) regarding its New Drug Application (NDA) for toremifene 80 mg to reduce fractures in men with prostate cancer receiving androgen deprivation therapy (ADT).

2 Nov 2009

Positive results from Aeterna Zentaris' AEZS-108 Phase 2 study in ovarian cancer patients

AEterna Zentaris Inc., a global biopharmaceutical company focused on endocrine therapy and oncology, today announced positive efficacy data from a Phase 2 study with its targeted cytotoxic peptide conjugate, AEZS-108 (formerly AN-152), in patients with platinum-resistant and taxane-pretreated ovarian cancer.

2 Nov 2009

New CyberKnife Robotic Radiosurgery System from Accuray

Accuray Incorporated, a global leader in the field of radiosurgery, announced today the introduction of the CyberKnife(®) VSI(TM) System, the latest addition to the CyberKnife product family.

1 Nov 2009

New diagnostic test for detecting colorectal cancer

GastroFISH™ is the first tissue-based fluorescence in situ hybridization (FISH) test for the detection of chromosomal anomalies associated with colon cancer.

31 Oct 2009

Accuray to focus on its CyberKnife Robotic Radiosurgery System at the ASTRO meeting

Accuray Incorporated, a global leader in the field of radiosurgery, announced today that 28 CyberKnife-focused abstracts have been accepted as part of the 51st Annual Meeting of the American Society for Radiation Oncology (ASTRO), taking place November 1 - 5 in Chicago, Illinois. This represents a 27 percent increase in CyberKnife abstracts over last year's Annual Meeting.

31 Oct 2009

NIH awards Charles Drew University $9.8M to reduce cancer health disparities in underserved populations

Charles Drew University has been awarded $9.8 million from three major national funders to support the university's long-term, UCLA partnership aimed at reducing the risk of cancer among minorities in poor and disadvantaged communities.

30 Oct 2009

Eisai reports global Phase III study results of eribulin mesylate

Eisai Inc. today announced preliminary results from a recently completed Phase III study with eribulin mesylate (E7389), discovered and developed by the company, in patients with locally advanced or metastatic breast cancer.

30 Oct 2009

ASTRO to host news briefings on top cancer research papers

The American Society for Radiation Oncology (ASTRO) will host four news briefings with accompanying live webcasts on the top cancer research papers from its 51st Annual Meeting.

30 Oct 2009

Studies demonstrate that investigational cancer vaccines show encouraging immune response rates

Results of two phase 1 studies demonstrate that the novel, investigational cancer vaccines MKC1106-MT and MKC1106-PP are well-tolerated and show encouraging immune response rates and objective tumor response in advanced melanoma, prostate cancer and other solid malignancies, setting the stage for phase 2 studies.

30 Oct 2009

Research provides new insight on gene fusion, a phenomenon known to cause prostate cancer

Researchers at the University of Michigan Comprehensive Cancer Center have discovered what leads to two genes fusing together, a phenomenon that has been shown to cause prostate cancer to develop.

30 Oct 2009

Study shows how differing Asian cultures and attitudes impact cancer screening rates

The Asian continent has nearly four billion people living in 47 different countries, and each of these groups has their own unique set of health issues. But when they come to the United States, they're often lumped into one large demographic: "Asian/Pacific Islander."

30 Oct 2009

TomoTherapy radiation therapy platform to be presented at the ASTRO Annual Meeting

TomoTherapy Incorporated announced today that several clinical presentations at the American Society for Radiation Oncology's 51st ASTRO Annual Meeting -- November 1-5, 2009 in Chicago -- will showcase the use of the TomoTherapy® radiation therapy platform as a vital component in the combined modality approach to treating cancer.

30 Oct 2009

World’s first Cesium-131 lung implants performed

IsoRay, Inc. announced today that starting on August 12, 2009, Dr. Bhupesh Parashar from the Department of Radiation Oncology, and Dr. Nasser Altorki of the Department of Cardiothoracic Surgery at Weill Cornell Medical Center performed the world’s first Cesium-131 lung implants.

29 Oct 2009

Third-quarter fiscal 2009 results announced by Endo Pharmaceuticals

Endo Pharmaceuticals today reported financial results for the third quarter of 2009.

29 Oct 2009

Protox Therapeutics to present Phase 2 study data of PRX302 for benign prostatic hyperplasia

Protox Therapeutics Inc., a leader in the development of receptor targeted fusion proteins, today announced that detailed data from its open-label Phase 2 clinical study of PRX302 in patients with moderate to severe benign prostatic hyperplasia (BPH) will be presented at the 30th World Congress of the Société Internationale d'Urologie Conference.

29 Oct 2009

Highlights of new cancer research to be presented at 51st ASTRO Annual Meeting

The following are highlights of new cancer research being presented at the American Society for Radiation Oncology's (ASTRO) 51st Annual Meeting on November 1-5, 2009, in Chicago.

29 Oct 2009

First nationwide Prostate Cancer registry for identifying effective treatment options

RemedyMD (www.RemedyMD.com), the leading provider of Patient registry software, today announced the first nationwide Prostate Cancer registry to help clinicians and researchers identify which interventions are most appropriate for specific patient populations.

28 Oct 2009

Prostate Cancer News and Research

Latest Prostate Cancer News and Research

Extra dose of proton radiation therapy reduces prostate cancer recurrences

superDimension launches the iLogic electromagnetic navigation bronchoscopy tool

Dendreon submits an amended BLA for PROVENGE active cellular immunotherapy

FDA issues a Complete Response Letter for GTx' toremifene NDA

Positive results from Aeterna Zentaris' AEZS-108 Phase 2 study in ovarian cancer patients

New CyberKnife Robotic Radiosurgery System from Accuray

New diagnostic test for detecting colorectal cancer

Accuray to focus on its CyberKnife Robotic Radiosurgery System at the ASTRO meeting

NIH awards Charles Drew University $9.8M to reduce cancer health disparities in underserved populations

Eisai reports global Phase III study results of eribulin mesylate

ASTRO to host news briefings on top cancer research papers

Studies demonstrate that investigational cancer vaccines show encouraging immune response rates

Research provides new insight on gene fusion, a phenomenon known to cause prostate cancer

Study shows how differing Asian cultures and attitudes impact cancer screening rates

TomoTherapy radiation therapy platform to be presented at the ASTRO Annual Meeting

World’s first Cesium-131 lung implants performed

Third-quarter fiscal 2009 results announced by Endo Pharmaceuticals

Protox Therapeutics to present Phase 2 study data of PRX302 for benign prostatic hyperplasia

Highlights of new cancer research to be presented at 51st ASTRO Annual Meeting

First nationwide Prostate Cancer registry for identifying effective treatment options

What to know about prostate cancer eBook

CellVoyant's AI-Powered Vision for the Future of Cell Therapy

Scalable, Smart, and Accessible: The Future of Lab Automation

Healthy Beginnings, Hopeful Futures: A Conversation with WHO’s Dr. Allotey

Prostate Cancer News and Research

Latest Prostate Cancer News and Research

What to know about prostate cancer eBook

CellVoyant's AI-Powered Vision for the Future of Cell Therapy

Scalable, Smart, and Accessible: The Future of Lab Automation

Healthy Beginnings, Hopeful Futures: A Conversation with WHO’s Dr. Allotey

Newsletters you may be interested in